Latest COO news and sentiment

HeartFlow (HTFL) Reports Q2 Loss, Beats Revenue Estimates

HeartFlow (HTFL) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to a loss of $1.46 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +50.00%. A quarter ago, it was expected that this medical technology company would post a loss of $0.18 per share when it actually produced a loss of $0.16, delivering a surprise of +11.11%. Over the last four quarters, the company has surpassed consensus EPS estimates three times. HeartFlow, which belongs to th

Revvity Launches SuperFlex Prenatal Screening System for Smaller Labs

Revvity, Inc. launched the SuperFlex prenatal screening system, a compact, CE-IVDR-certified automated immunoassay instrument designed for small to mid-sized laboratories and clinics. This system aims to expand access to prenatal and preeclampsia testing with its ability to process up to 60 tests per hour and deliver results quickly. The launch is expected to strengthen Revvity's position in the reproductive health market and capitalize on the growing demand for preeclampsia screening.

Mercury Systems (NASDAQ:MRCY) Upgraded to Strong-Buy at Piper Sandler

Piper Sandler upgraded Mercury Systems (NASDAQ:MRCY) to a "strong-buy" rating, aligning with Truist Financial's similar rating. The company holds an overall "Moderate Buy" analyst consensus with an average price target of $102. Mercury Systems' shares opened at $111.64, and the company has seen recent insider selling by director Howard L. Lance, who sold 9,250 shares.

Staar Surgical (STAA) Surpasses Q2 Earnings and Revenue Estimates

Staar Surgical (STAA) came out with quarterly earnings of $0.31 per share, beating the Zacks Consensus Estimate of $0.21 per share. This compares to a loss of $0.07 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +47.62%. A quarter ago, it was expected that this maker of implantable lenses would post earnings of $0.13 per share when it actually produced earnings of $0.38, delivering a surprise of +192.31%. Over the last four quarters, the company has surpassed consensus EPS estimates three times. Staar Surgical,

Here's Why You Should Add BrightSpring Stock to Your Portfolio Now

BrightSpring Health Services, Inc. BTSG is well-poised for growth in the coming quarters, backed by strong momentum in Provider Services, expanding specialty and infusion operations, successful integration of acquired home health assets and a scalable home-based care platform. However, the Inflation Reduction Act (IRA)-related reimbursement pressure, brand-to-generic conversion headwinds and customer exits in Home and Community Pharmacy could create uneven growth trends and weigh on near-term margin realization through 2026. This Zacks Rank #1 (Strong Buy) company's shares have rallied 54.6% in the year-to-date period against the industry's 1.1% decline. However, the S&P 500 has risen 12.5% during the same timeframe. Headquartered in Louisville, KY, the company holds a market capitalization of $12.16 billion. BTSG is a national home and community-based healthcare services platform integrating pharmacy and provider care for medically complex patients across Medicare, Medicaid and commercial payors. The company serves 50 states and focuses on seniors and specialty populations in lower-cost home and community settings. Its forward P/E ratio of 41.80 is significantly higher than the industry average of 16.74.Zacks Investment Research Image Source: Zacks Investment Research Let's delve deeper. BTSG's Growth Drivers Specialty and Infusion Remain Key Growth Engines: Specialty and Infusion continued to lead Pharmacy Solutions, with second-quarter 2026 revenues rising 30% year over year to $2.9 billion, supported by branded LDDs, new launches, generic growth, fee-for-service programs and strong execution. Script growth reached 31%, while BrightSpring added two ultra-narrow LDDs, taking its portfolio to 155, with 12 LDDs launched year to date. Infusion delivered strong volume growth, including more than 20% growth in acute infusion and nearly 20% in chronic infusion. The company plans to expand into 12-15 additional states over the next five years, while concierge programs, AI-enabled intake and greater integration with Pharmacy Solutions should support longer-term growth. Provider Services Momentum and Integration: Provider Services revenues increased 30% year over year to $466 million, led by Home Health Care, where revenues jumped 51% on strong census growth, de novo expansion, preferred MA/ACO contracts and Amedisys/LHC contributions. The acquired branches contributed $78 million of revenues and $8 million of adjusted EBITDA in the second quarter, while BrightSpring raised its 2026 EBITDA contribution expectation for these assets to approximately $35 million as integration progresses well. Nearly 95% of Home Health branches now carry four-star or better ratings, supporting referral growth and payer relationships. Story Continues Platform Scale and Margin Conversion: BrightSpring's integrated pharmacy and provider platform serves large home and community healthcare markets where payors seek coordinated, lower-cost care. Second-quarter 2026 results showed broad-based growth and faster adjusted EBITDA expansion, driven by purchasing efficiencies, standardized operations, technology and automation. Management expects EBITDA to outpace revenue growth as efficiencies and mix improve, with approximately $600 million in operating cash flow and leverage below 2x before acquisitions to support disciplined reinvestment and growth. BTSG Stock: Key Risks to Watch IRA-Related Revenue Pressure: IRA-related reimbursement changes and brand-to-generic conversions continue to weigh on reported pharmacy revenues despite improving volumes and profitability. Home and Community Pharmacy absorbed an approximately $50 million IRA impact in the second quarter of 2026, with about $45 million expected in each remaining quarter, implying a roughly $200 million full-year impact. While higher volume, mix and execution supported BrightSpring's raised 2026 guidance, reimbursement resets may create uneven quarterly growth and complicate comparisons until the busines

NPCE Q2 Earnings Beat Estimates on RNS Growth, '26 Revenue View Up

NeuroPace (NPCE) reported strong second-quarter 2026 results, with earnings and revenues surpassing Zacks Consensus Estimates, driven by significant growth in its RNS System. The company also raised its full-year 2026 revenue guidance and improved its adjusted EBITDA loss outlook. NeuroPace highlighted advancements in AI-based clinical decision-support tools and progress in its idiopathic generalized epilepsy program, signaling continued innovation and market expansion.

Alcon’s New-Product Wave Carries Q2 As It Walks Away From Accommodating IOL Bet

Alcon's Q2 performance was boosted by new product introductions, a strategy that comes as the company anticipates a $60 million refund from the US government. Alcon plans to reinvest approximately two-thirds of this refund back into its business operations. This move also signifies Alcon's shift away from its bet on accommodating intraocular lenses (IOLs).

Mizuho raises Alcon stock price target to $85 on new products

Mizuho has increased its price target for Alcon Inc. (NYSE:ALC) shares from $80 to $85, maintaining an Outperform rating, due to anticipated new product growth from Unity VCS and Tryptyr in Q2 2026. Despite headwinds in certain divisions like Implantables, Panoptix Pro share gains are providing an offset, and the firm expects continued strong performance from its ophthalmology portfolio. Alcon recently reported strong Q2 fiscal 2026 results and engaged in strategic collaborations, reinforcing its position in the medtech market.

CAH Q4 Earnings Beat on Pharma Strength, Revenues Miss, Stock Up

Cardinal Health, Inc. CAH reported fourth-quarter fiscal 2026 adjusted earnings per share (EPS) of $2.91, beating the Zacks Consensus Estimate by 20.3%. The bottom line improved 40% year over year, aided by higher operating earnings, IEEPA tariff refunds, a lower tax rate and a reduced share count. GAAP EPS in the quarter was $1.70 compared with $1.00 in the year-ago period. Full-year fiscal 2026 adjusted EPS was $11.26, up 37% compared to the figure at the end of the fiscal 2025 period. The company reported GAAP EPS of $7.23 in fiscal 2026, compared with $6.45 in the year-ago period. Q4 Reven

RDNT Q2 Earnings & Sales Beat on Advanced Imaging, Guidance Raised

RadNet, Inc. RDNT reported second-quarter 2026 adjusted earnings of 29 cents per share, down 14.7% year over year but ahead of the Zacks Consensus Estimate of 18 cents by 61.1%. GAAP EPS was 10 cents compared with 19 cents in the prior-year period. Growth was led by stronger advanced imaging volumes, recent acquisitions and Digital Health expansion. Annual recurring revenues, or ARR, in Digital Health reached $105.5 million, up 97% year over year. Revenue Details Revenues rose 25% to $622.7 million, topping the consensus mark by 1.4%. RadNet's share price improvement of 8.3% so far this year h

Cardinal Health (CAH) Q4 Earnings Beat Estimates

Cardinal Health (CAH) reported Q4 earnings of $2.91 per share, surpassing the Zacks Consensus Estimate of $2.42, marking a 20.25% surprise. While earnings beat expectations, the company's revenues of $63.67 billion missed the consensus estimate

Inogen Q2 Earnings Beat Estimates, Sales Rise Y/Y, 2026 View Cut

Inogen, Inc. INGN reported breakeven earnings for second-quarter 2026, compared to the year-ago period's adjusted loss of 2 cents per share. GAAP loss per share of 14 cents, narrower than the year-ago loss of 15 cents. The figure beat the Zacks Consensus Estimate by 17.7%. Year to date, the company's shares have lost 10% compared with the industry's fall of 8.5%. However, the S&P 500 Index has increased 13.1% in the same time frame.Zacks Investment Research Image Source: Zacks Investment Research INGN's Q2 Revenues in Detail Inogen registered revenues of $95.1 million for the second quarter of

iRhythm Q2 Earnings Beat Estimates on Volume Growth, '26 View Raised

iRhythm Holdings, Inc. IRTC reported adjusted earnings per share of 58 cents in the second quarter of 2026, against an adjusted loss per share of 32 cents a year ago. The figure beat the Zacks Consensus Estimate by 5900%. GAAP loss per share for the quarter was 1 cent compared with 44 cents in the year-ago period. IRTC's Q2 Revenues in Detail iRhythm registered revenues of $224.2 million in the second quarter, up 20.1% year over year. The increase was primarily driven by sustained volume demand across the customer base, reflecting continued strength in the core business and contributions from

Assenagon Asset Management S.A. Buys 457,938 Shares of The Cooper Companies, Inc. $COO

Assenagon Asset Management S.A. significantly increased its stake in The Cooper Companies (NASDAQ:COO) by 674.1% in the second quarter, purchasing 457,938 additional shares to own a total of 525,872 shares valued at $37.7 million. This move is part of a broader trend of institutional investment, with several other major funds also expanding their positions, bringing total institutional ownership to 24.39%. The Cooper Companies recently surpassed quarterly earnings and revenue estimates, reporting $1.21 EPS and $1.08 billion in revenue, while analysts maintain a consensus "Hold" rating with an average price target of $81.36.

Could Zacks’ Upgrade Reveal a Shift in Cooper Companies’ (COO) Earnings Quality Narrative?

Zacks recently upgraded The Cooper Companies (COO) to a Rank #2 (Buy) due to raised earnings estimates and a stronger near-term outlook. This upgrade suggests an improved earnings profile that could attract value-focused investors, despite existing pressures like competitive pricing and segment weaknesses. The article explores how this new outlook, alongside a consistent share repurchase program, may reshape the investment narrative for Cooper Companies.

XRAY Stock Falls Despite Q2 Earnings Beat, Wellspect Drives Sales

DENTSPLY SIRONA Inc. XRAY reported second-quarter 2026 adjusted earnings per share (EPS) of 52 cents, down 1.6% year over year on an actual-value basis. The bottom line beat the Zacks Consensus Estimate of 36 cents by 44.4%. GAAP EPS in the quarter was 18 cents against loss per share of 22 cents in the prior-year quarter. XRAY's Revenue Trends and Regional Mix Revenues declined 4.1% reportedly to $898 million and 6.3% at constant currency (cc). The metric, however, beat the Zacks Consensus Estimate by 1.6%. Weakness across three dental segments weighed on sales, partly offset by Wellspect Heal

Bausch + Lomb Announces Board of Directors Update, Reaffirms Guidance

Bausch + Lomb (NYSE/TSX: BLCO) announced changes to its Board of Directors, with four new appointments effective August 5, 2026, at the request of majority owner Bausch Health Companies Inc. The company also reaffirmed its full-year 2026 guidance for revenue between $5.440 billion and $5.540 billion and Adjusted EBITDA excluding Acquired IPR&D between $1.025 billion and $1.075 billion. This follows a strong second-quarter performance with 9% revenue growth and significant margin expansion.

Henry Schein, Inc. (HSIC) Hits Fresh High: Is There Still Room to Run?

Henry Schein, Inc. (HSIC) recently hit a new 52-week high of $92.18, with shares up 2.6% over the past month and 17.9% year-to-date. The company has consistently beaten earnings estimates, reporting strong EPS and revenue growth. With a Zacks Rank of #2 (Buy) and favorable valuation metrics, analysts suggest there might still be room for the stock to appreciate further.

Bank of Nova Scotia Has $1.95 Million Stake in The Cooper Companies, Inc. $COO

Bank of Nova Scotia significantly reduced its stake in The Cooper Companies by 88.2% in the first quarter, selling over 200,000 shares but still retaining shares worth approximately $1.95 million. Despite this, other major institutional investors increased their holdings, with institutional ownership collectively at 24.39%. Cooper Companies surpassed its quarterly earnings and revenue estimates, maintaining a consensus "Hold" rating from analysts.

Business First Bancshares (NASDAQ:BFST) COO Sells $134,736.00 in Stock